Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3485-3492

  Zuzak, Tycho J ^a,b,c   Rist, L ^b   Eggenschwiler, J ^a   Grotzer, M A ^c   Viviani, A ^a  

^a ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

^b Paracelsus Hospital   (Switzerland)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Brain tumour; Childhood cancer; Complementary and alternative medicine; Medulloblastoma; Mistletoe

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; LECTIN; VISCUM ALBUM EXTRACT;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER CELL; CANCER CELL CULTURE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAINING; UNSPECIFIED SIDE EFFECT; VISCUM ALBUM;

ANNEXIN A5; APOPTOSIS; CASPASES; CHILD; FLOW CYTOMETRY; HUMANS; LECTINS; MEDULLOBLASTOMA; MISTLETOE; MITOCHONDRIA; NECROSIS; PLANT EXTRACTS; PLANT PREPARATIONS; TUMOR CELLS, CULTURED; VISCUM ALBUM;

EID: 33750694218     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Gurney JG, Wall DA, Jukich PJ and Davis FG: The contribution of nonmalignant tumors to CNS tumor incidence rates among children in the United States. Cancer Causes Control 10(2): 101-105, 1999.
2. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM et al: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17(3): 832-845, 1999.
3. Graham ML, Herndon JE, 2nd, Casey JR, Chaffee S, Ciocci GH, Krischer JP et al: High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 15(5): 1814-1823, 1997.
4. Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH Jr, Bostrom BC et al: High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol 16(1): 222-228, 1998.
5. Kellie SJ: Chemotherapy of central nervous system tumours in infants. Childs Nerv Syst 15(10): 592-612, 1999.
6. Mulhern RK, Horowitz ME, Kovnar EH, Langston J, Sanford RA and Kun LE: Neurodevelopmental status of infants and young children treated for brain tumors with preirradiation chemotherapy. J Clin Oncol 7(11): 1660-1666, 1989.
7. Jenkin D, Danjoux C and Greenberg M: Subsequent quality of life for children irradiated for a brain tumor before age four years. Med Pediatr Oncol 31(6): 506-511, 1998.
8. Kiltie AE, Lashford LS and Gattamaneni HR: Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol 28(5): 348-354, 1997.
9. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J et al: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24(1): 303-309, 2004.
10. Neuhouser ML, Patterson RE, Schwartz SM, Hedderson MM, Bowen DJ and Standish LJ: Use of alternative medicine by children with cancer in Washington state. Prev Med 33(5): 347-354, 2001.
11. Martel D, Bussieres JF, Theoret Y, Lebel D, Kish S, Moghrabi A et al: Use of alternative and complementary therapies in children with cancer. Pediatr Blood Cancer 44(7): 660-668, 2005.
12. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V et al: Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16(4): 655-663, 2005.
13. Stein GM and Berg PA: Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs 8 Suppl 1: S39-42, 1997.
14. Stein G, Henn W, von Laue H and Berg P: Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur J Med Res 3(4): 194-202, 1998.
15. Bussing A and Schietzel M: Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res 19(1A): 23-28, 1999.
16. Harmsma M, Gromme M, Ummelen M, Dignef W, Tusenius KJ and Ramaekers FC: Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells. Int J Oncol 25(6): 1521-1529, 2004.
17. Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S and Kiene H: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8(3): 109-119, 2003.
18. Lenard HG, Engelbrecht V, Janssen G, Wechsler W, Tautz C. Complete remission of a diffuse pontine glioma. Neuropediatrics 29(6): 328-330, 1998.
19. Lenartz D, Andermahr J, Plum G, Menzel J and Beuth J: Efficiency of treatment with galactoside-specific lectin from mistletoe against rat glioma. Anticancer Res 18(2A): 1011-1014, 1998.
20. Lenartz D, Dott U, Menzel J, Schierholz JM and Beuth J: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20(3B): 2073-2076, 2000.
21. Musielski H and Rüger K: Verfahren zur Erfassung von Mistellektinen in Mistelextrakten und Mistellektin-spezifischen Immunglobulinen. Deutsches Patent DP 4424275.1, 1996.
22. Eggenschwiler J, Knoepfel-Siedler F, Werner M, Ramos M, Rist L and Viviani A: Cytotocity of Iscador P, A, M and Qu on cell lines in vitro. Annual Conference of the Anthroposophic Medical Movement, September 25th to 28th, Dornach, Switzerland, 2005.
23. Zuzak TJ, Eggenschwiler J, Rist L and Viviani A: Extracts from dried Viscum album have their own response profiles in vitro. Under subscription, 2006.
24. Bussing A, Suzart K, Bergmann J, Pfuller U, Schietzel M and Schweizer K: Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett 99(1): 59-72, 1996.
25. Duong Van Huyen JP, Delignat S, Kazatchkine MD and Kaveri SV: Comparative study of the sensitivity of lymphoblastoid and transformed monocytic cell lines to the cytotoxic effects of Viscum album extracts of different origin. Chemotherapy 49(6): 298-302, 2003.
26. Hulsen H DC and Mechelke F: Differences in the in vitro effectiveness of preparations produced from mistletoes of various host trees. Arzneimittelforschung 36(3): 433-436, 1986.
27. Elsasser-Beile U, Leiber C, Wolf P, Lucht M, Mengs U and Wetterauer U: Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol 174(1): 76-79, 2005.
28. Burger AM, Mengs U, Schuler JB and Fiebig HH: Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro. Arzneimittelforschung 51(9): 748-757, 2001.
29. Eggenschwiler J, A. Patrignani A, Wagner U, Rehrauer H, Schlapbach R, Rist L, Ramos M and Viviani A: Responsiveness of different breast cancer cells to Viscum album preparations using cDNA microarrys. Submitted to Drug Research, 2005.
30. Duong Van Huyen JP, Sooryanarayana, Delignat S, Bloch MF, Kazatchkine MD and Kaveri SV: Variable sensitivity of lymphoblastoid cells to apoptosis induced by Viscum album Qu FrF, a therapeutic preparation of mistletoe lectin. Chemotherapy 47(5): 366-376, 2001.
31. Van Huyen JP, Bayry J, Delignat S, Gaston AT, Michel O, Bruneval P et al: Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Mol Med 8(10): 600-606, 2002.
32. Bussing A, Wagner M, Wagner B, Stein GM, Schietzel M, Schaller G et al: Induction of mitochondrial Apo2.7 molecules and generation of reactive oxygen-intermediates in cultured lymphocytes by the toxic proteins from Viscum album L. Cancer Lett 139(1): 79-88, 1999.
33. Heiny BM and Beuth J: Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14(3B): 1339-1342, 1994.
34. Beuth J: Clinical relevance of immunoactive mistletoe lectin-I. Anticancer Drugs 8 Suppl 1: S53-55, 1997.
35. Beuth J, Gabius HJ, Steuer MK, Geisel J, Steuer M, Ko HL et al: Effect of mistletoe lectin therapy on serum level of defined serum proteins (acute phase proteins) in tumor patients. Med Klin (Munich) 88(5): 287-290, 1993.
36. Beuth J, Ko HL, Gabius HJ, Burrichter H, Oette K and Pulverer G: Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clin Investig 70(8): 658-661, 1992.
37. Chernyshov VP, Heusser P, Omelchenko LI, Chernyshova LI, Vodyanik MA, Vykhovanets EV et al: Immunomodulatory and clinical effects of Viscum album (Iscador M and Iscador P) in children with recurrent respiratory infections as a result of the Chernobyl nuclear accident. Am J Ther 7(3): 195-203, 2000.
38. Franz-H A-J, Bachler-B, Habdedank-S, Taube-F and Niedobitek-F: Lectin-histochemical demonstration of microglia in the central nervous system of AIDS patients using mistletoe lectin I (ML I) Lectins. Biol. Biochem. Clinical Biochem. van Driessche E et al. (eds.) 8: 64-69, 1993.
39. Franz H: The use of mistletoe lectin I in brain histochemistry Ergebnisse der experimentellen Medizin 51: 216-224, 1990.
40. Ruggiero A, Conter V, Milani M, Biagi E, Lazzareschi I, Sparano P et al: Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs 3(4): 237-246, 2001.